Kristie L. Kahl

Articles

Frontline Pembrolizumab Bests Chemo in NSCLC, Especially in PD-L1-High Subgroup

June 3rd 2018

Patients with non-small cell lung cancer treated with frontline pembrolizuma lived 4 to 8 months longer than those who received standard of care chemotherapy.

Microsatellite Instability Status Links to Lynch Syndrome in Broad Array of Cancers

June 2nd 2018

Microsatellite instability-high tumors are more likely to be associated with the presence of Lynch syndrome. Yet, 45% of patients with cancers not typically identified with Lynch syndrome actually qualify for germline genetic testing.

Compared With Men, Women With Head and Neck Cancer Undertreated

June 1st 2018

Women with head and neck cancer may be severely undertreated and have higher death rates compared with their male counterparts.

TLR9 Agonist May Reverse Resistance to PD-1 Inhibition in Melanoma

April 17th 2018

Combination use of CMP-001, an intratumoral toll-like receptor 9 agonist, and pembrolizumab (Keytruda) showed clinical activity in reversing PD-1 checkpoint inhibition resistance in patients with metastatic melanoma.

FT819 Derives Renewable, Reproducible Process of CAR T-Cell Therapy

April 16th 2018

An off-the-shelf, dual-targeted chimeric antigen receptor T-cell approach yielded positive results in preclinical specificity, functionality, and efficacy studies.

BLU-667 Shows Promise for Advanced Solid Tumors With RET Alterations

April 15th 2018

BLU-667, a next-generation tyrosine kinase inhibitor, appeared to be well-tolerated and had broad clinical benefit among patients with advanced, RET-altered solid tumors who progressed on prior therapies.

Combination Regimen Safe, Effective as Salvage Therapy for Relapsed/Refractory Hodgkin Lymphoma

December 11th 2017

Brentuximab vedotin (Adcetris) plus nivolumab (Opdivo) appeared active and well tolerated for the treatment of patients with relapsed/refractory Hodgkin lymphoma.

Curative Approach Improves Responses in Patients With Smoldering Multiple Myeloma

December 11th 2017

A novel approach demonstrated durable responses in the treatment of patients with smoldering multiple myeloma, according to results from a single-arm, phase II trial.

Alternative Agent Shows Clinical Activity in Patients With Advanced Systemic Mastocytosis

December 10th 2017

Treatment using BLU-285 (Avapritinib) induced clinically significant activity in patients with an advanced or aggressive form of systemic mastocytosis, according to data from an ongoing phase I trial.

Direct Oral Anticoagulant Prevents VTE Recurrence in Select Patients With Cancer

December 9th 2017

Treatment using oral rivaroxaban (Xarelto) reduced venous thromboembolism (VTE) recurrence among patients with cancer, according to results from the select-d trial.

Acupuncture Reduces AI-Associated Joint Pain in Women with Breast Cancer

December 7th 2017

A mix of traditional and customized acupuncture techniques proved effective in reducing pain and stiffness associated with aromatase inhibitor (AI) therapy in women with early-stage breast cancer.

Alternative Chemotherapy Dosing Strategies Improve Breast Cancer Outcomes

December 6th 2017

Shortening the intervals between chemotherapy cycles or administering the drugs sequentially reduced early-stage breast cancer recurrence and mortality compared with standard dosing techniques.